調査レポートカテゴリー： Infiniti Research TechNavio, 世界

Global Chronic Lymphocytic Leukemia Therapeutics Market 2015-2019

慢性リンパ性白血病（CLL）治療薬の世界市場2015-2019

◆タイトル：Global Chronic Lymphocytic Leukemia Therapeutics Market 2015-2019
◆商品コード：IRTNTR6598
◆調査・発行会社：Technavio (Infiniti Research Ltd.)
◆発行日：2015年8月5日
◆ページ数：87
◆資料形式：pdf / 英語
◆納品方法：Eメール
◆調査対象地域：グローバル
◆産業分野：製薬・医療
◆販売価格オプション（消費税別）
Single UserUSD2,500 ⇒換算￥272,500見積依頼/購入/質問フォーム
Five UserUSD3,000 ⇒換算￥327,000見積依頼/購入/質問フォーム
Enterprise License（全社内共有可）USD4,000 ⇒換算￥436,000見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※Eメールによる納品の場合、通常ご注文当日～2日以内に納品致します。
※商品の納品後、納品日＋5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。（振込先：三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社）
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※ご購入後、資料に記載の英語表現や単語の意味に関しましては無料でお答えいたします。（但し、対応範囲は弊社で判断）
※弊社H&Iグローバルリサーチ株式会社はTechnavio (Infiniti Research Ltd.)の日本における正規販売代理店です。

 【資料の概要】

当調査レポートでは、慢性リンパ性白血病（CLL）治療薬の世界市場について調査・分析し、エグゼクティブサマリー、市場概観、業界の構造分析、慢性リンパ性白血病（CLL）治療薬の世界市場規模及び予測、種類別分析、投与経路（ROA）別分析、市場シェア、地域別分析、購買基準、市場成長要因、市場の課題、市場動向、競争状況、主要企業（ベンダー）分析などの情報をお届けいたします。

About Chronic Lymphocytic Leukemia
Chronic lymphocytic leukemia is a malignant condition characterized by increased production of lymphocytes. It has been observed that the cancer first affects B-lymphocytes and then it can spread to other parts of the body. This leukemia is diagnosed mostly at later stages because of the slow buildup of the cancerous cells. During the course of the disease, the malignancy spreads to the spleen, liver, and lymph nodes. The course of the disease is heterogeneous, and prognosis is difficult. Symptoms include swelling of the lymph nodes, fatigue, fever, infection, pain beneath the ribs, and weight loss. Chronic lymphocytic leukemia can be treated with radiation, steroids, chemotherapy, targeted therapy, transplants (bone marrow, stem cell), and surgical procedure to remove the spleen (splenectomy).

Technavio’s analysts forecast the global chronic lymphocytic leukemia therapeutics market to grow at a CAGR of 18.52% over the period 2014-2019.

[Covered in this Report]
In this report, Technavio covers the present scenario and growth prospects of the global chronic lymphocytic leukemia therapeutics market for the period 2015-2019. To calculate the market size, we consider revenue generated from the sales of various drugs used in the treatment of chronic lymphocytic leukemia.

Based on the type of molecule, we group the market into two categories:
• Biologics
• Small molecules

Based on the route of administration, we group the market into two:
• Oral
• Parenteral

This report includes a discussion of the market in the following three regions:
• Americas: The major countries focused in the Americas are the US, Canada, Mexico, and Brazil
• EMEA: The major countries in this region are the UK, Germany, Italy, France, Spain and Middle

Eastern and African countries such as Israel, South Africa, Egypt, Sudan, Kuwait, Saudi Arabia, Qatar, and the UAE

• APAC: The major countries in this region are Japan, China, Australia, Singapore, South Korea, and India. APAC is a major untapped market with many leading vendors in the global chronic lymphocytic leukemia therapeutics market.

The report also presents the vendor landscape and a corresponding detailed analysis of the top vendors in the market. In addition, it discusses the major drivers and challenges, as well as the key trends.

[Key Regions]
• Americas
• APAC
• EMEA

[Key Vendors]
• F. Hoffmann-La Roche
• Novartis
• Teva Pharmaceutical Industries

[Other Prominent Vendors]
• Actavis
• Amgen
• Aryogen
• Astellas
• Bristol-Myers Squibb
• Eagle Pharmaceuticals
• Eisai
• Fresenius Kabi
• Genmab
• Gilead Sciences
• H. Lundbeck
• Hospira
• idd biotech
• Immunomedics
• Johnson & Johnson
• Mundipharma
• Mylan
• Noxxon
• Ono Pharmaceutical
• PDL BioPharma
• Pfizer
• Pharmacyclics
• Regeneron
• Sagent Pharmaceutical
• Sanofi
• SymBio Pharmaceuticals
• TheraMAB

[Market Driver]
• Increase in Patient Pool
• For a full, detailed list, view our report

[Market Challenge]
• Unknown Disease Etiology
• For a full, detailed list, view our report

[Market Trend]
• Strategic Alliances
• For a full, detailed list, view our report

[Key Questions Answered in this Report]
• What will the market size be in 2019 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?

【資料の目次】

01. Executive Summary

02.List of Abbreviations

03.Scope of the Report
03.1 Market Overview
03.2 Product Offerings

04.Product Profiles
04.1.1 Gazyva/Gazyvaro
04.1.2 MabThera/Rituxan
04.1.3 Arzerra
04.1.4 Treanda

05.Market Research Methodology
05.1 Market Research Process
05.2 Research Methodology

06.Disease Overview
06.1 Understanding the Disease
06.2 Types of Chronic Lymphocytic Leukemia
06.3 Symptoms
06.4 Diagnosis
06.5 Staging
06.6 Epidemiology
06.7 Management
06.8 Economic Burden

07.Introduction

08.Market Landscape
08.1 Market Overview
08.2 Market Size and Forecast
08.3 Five Forces Analysis

09.Pipeline Portfolio
09.1 Key Information on the Major Pipeline Molecules
09.1.1 RG 105 SC Formulation
09.1.2 Obinutuzumab/ Venetoclax
09.1.3 RG 7596 (Polatuzumab vedotin)
09.1.4 RG 7601 (Venetoclax)

10.Market Segmentation by Route of Administration
10.1 Oral
10.2 Parenteral

11.Market Segmentation by Type of Molecule
11.1 Small Molecules
11.2 Biologics

12.Geographical Segmentation

13.Buying Criteria

14.Market Growth Drivers

15.Drivers and their Impact

16.Market Challenges

17.Impact of Drivers and Challenges

18.Market Trends

19.Trends and their Impact

20.Vendor Landscape
20.1 Competitive Scenario
20.1.1 Key News
20.1.2 Mergers and Acquisitions
20.2 Market Share Analysis 2014
20.2.1 F. Hoffmann-La Roche
20.2.2 Teva Pharmaceutical Industries
20.2.3 Novartis
20.3 Other and Future Prominent Vendors

21.Key Vendor Analysis
21.1 F. Hoffmann-La Roche
21.1.1 Key Facts
21.1.2 Business Overview
21.1.3 Business Segmentation
21.1.4 Business Segmentation by Revenue 2012 and 2013
21.1.5 Sales by Geography
21.1.6 Business Strategy
21.1.7 Key Information
21.1.8 SWOT Analysis
21.2 Novartis
21.2.1 Key Facts
21.2.2 Business Description
21.2.3 Business Segmentation
21.2.4 Revenue by Business Segmentation
21.2.5 Revenue Comparison 2012 and 2013
21.2.6 Sales by Geography
21.2.7 Business Strategy
21.2.8 Key Developments
21.2.9 SWOT Analysis
21.3 Teva Pharmaceutical Industries
21.3.1 Key Facts
21.3.2 Business Overview
21.3.3 Business Segmentation
21.3.4 Revenue by Business Segmentation
21.3.5 Revenue Comparison 2012 and 2013
21.3.6 Revenue Segmentation by Geography
21.3.7 Business Strategy
21.3.8 Key Developments
21.3.9 SWOT Analysis

22.Other Reports in this Series

[List of Exhibits]

Exhibit 1: Market Research Methodology
Exhibit 2: Snapshot of Chronic Lymphocytic Leukemia
Exhibit 3: Type of Chronic Lymphocytic Leukemia
Exhibit 4: Major Diagnostic Procedures to Determine Chronic Lymphocytic Leukemia
Exhibit 5: Other Diagnostic Procedures to Determine Chronic Lymphocytic Leukemia
Exhibit 6: Rai Staging of Chronic Lymphocytic Leukemia
Exhibit 7: Binet Staging of Chronic Lymphocytic Leukemia
Exhibit 8: Management of Chronic Lymphocytic Leukemia
Exhibit 9: Economic Burden of Chronic Lymphocytic Leukemia
Exhibit 10: Global Chronic Lymphocytic Leukemia Therapeutics Market 2014-2019 ($ millions)
Exhibit 11: Key Takeaways: Global Chronic Lymphocytic Leukemia Therapeutics Market
Exhibit 12: Drug Candidates by Stage of Development, in percentage
Exhibit 13: Segmentation of Global Chronic Lymphocytic Leukemia Therapeutics Market by Route of Administration
Exhibit 14: Segmentation of Global Chronic Lymphocytic Leukemia Therapeutics Market by Type of Molecules
Exhibit 15: Segmentation of Global Chronic Lymphocytic Leukemia Therapeutics Market by Geography, 2014
Exhibit 16: Drivers of Global Chronic Lymphocytic Leukemia Therapeutics Market
Exhibit 17: Challenges of Global Chronic Lymphocytic Leukemia Therapeutics Market
Exhibit 18: Trends of Global Chronic Lymphocytic Leukemia Therapeutics Market
Exhibit 19: Global Sales and YoY Growth Rate of Rituxan/MabThera 2010-2014 ($ millions)
Exhibit 20: Global Sales and YoY Growth Rate of Treanda 2010-2014 ($ millions)
Exhibit 21: Global Sales and YoY Growth Rate of Arzerra 2010-2014($ millions)
Exhibit 22: Sales and YoY Growth Rate of Arzerra in US 2010-2014 ($ millions)
Exhibit 23: Sales and YoY Growth Rate of Arzerra in Europe 2010-2014 ($ millions)
Exhibit 24: Region-wise Revenue Comparison of Arzerra 2010-2014 ($ millions)
Exhibit 25: Business Segmentation of F. Hoffmann-La Roche Ltd. 2013
Exhibit 26: F. Hoffmann-La Roche Ltd.: Business Segmentation by Revenue 2012 and 2013
Exhibit 27: F. Hoffmann-La Roche Ltd.: Sales by Geography 2013 (Pharmaceuticals Division)
Exhibit 28: F. Hoffmann-La Roche Ltd.: Sales by Geography 2013 (Diagnostics Division)
Exhibit 29: Novartis AG: Business Segmentation
Exhibit 30: Novartis AG: Revenue by Business Segmentation 2013
Exhibit 31: Novartis AG: Revenue by Business Segmentation 2012 and 2013 ($ millions)
Exhibit 32: Novartis AG: Revenue by Geographical Segmentation 2013
Exhibit 33: Teva Pharmaceutical Industries Ltd.: Business Segmentation
Exhibit 34: Teva Pharmaceutical Industries Ltd.: Revenue by Business Segmentation 2013
Exhibit 35: Teva Pharmaceutical Industries Ltd.: Revenue by Business Segmentation 2012 and 2013 ($ millions)
Exhibit 36: Teva Pharmaceutical Industries Ltd.: Revenue by Geographical Segmentation 2013



【掲載企業】

F. Hoffmann-La Roche, Novartis and Teva Pharmaceutical Industries, Actavis, Amgen, Aryogen, Astellas, Bristol-Myers Squibb, Eagle Pharmaceuticals, Eisai, Fresenius Kabi, Genmab, Gilead Sciences, H. Lundbeck, Hospira, idd biotech, Immunomedics, Johnson & Johnson, Mundipharma, Mylan, Noxxon, Ono Pharmaceutical

【資料のキーワード】

慢性リンパ性白血病（CLL）治療薬、白血病、治療、医薬品、パイプライン

【調査方法】

一次資料による調査（業界専門家、ベンダー、代理店、顧客等を対象にしたデプスインタビュー調査など）及び二次資料による調査（Technavio独自のプラットフォーム、産業書籍、企業報告書、ニュース記事、アナリストレポート、貿易協会、政府機関発行データなど）

★調査レポート[慢性リンパ性白血病（CLL）治療薬の世界市場2015-2019] (Global Chronic Lymphocytic Leukemia Therapeutics Market 2015-2019 / IRTNTR6598)販売に関する免責事項
[慢性リンパ性白血病（CLL）治療薬の世界市場2015-2019] (Global Chronic Lymphocytic Leukemia Therapeutics Market 2015-2019 / IRTNTR6598)についてEメールでお問い合わせ
◆関連調査資料◆
  • 白血病治療薬の世界市場：慢性リンパ性白血病、急性リンパ性白血病、急性骨髄性白血病、慢性骨髄性白血病
    IRTNTR10286 / Technavio / 2016年9月20日 / 当調査レポートでは、白血病治療薬の世界市場について調査・分析し、エグゼクティブサマリー、市場概観、市場概観、業界の構造分析、白血病治療薬の世界市場規模及び予測、疾患種類別分析、地域別分析/市場規模、市場の成長要因、市場の課題、市場動向、競争状況、主要企業（ベンダー）分析などの情報をお届けいたします。...About Leukemia Cancer that starts from hematopoietic stem cells of the bone marrow is referred to as leukemia. Leukemia can be chronic or acute depending on the maturity of the cells. Also, based on the bone marrow cells from which cancer starts, leukemia can be categorized as lymphocytic or myeloid. Technavio’s analysts forecast the leukemia therapeutics market to grow at a CAGR of 8.44% during the period 2016-2020. [Covered in this report] The report covers the present scenario and the growth prospects of the leukemia therapeutics market for 2016-2020. To calculate the market size, the report considers the the revenue...
  • 慢性リンパ性白血病（CLL）治療薬の世界市場2016-2020
    IRTNTR9378 / Technavio / 2016年6月1日 / 当調査レポートでは、慢性リンパ性白血病（CLL）治療薬の世界市場について調査・分析し、エグゼクティブサマリー、市場概観、市場概観、業界の構造分析、疾患概要、慢性リンパ性白血病（CLL）治療薬の世界市場規模及び予測、種類別分析、市場シェア、地域別分析/市場規模、購買基準、市場の成長要因、市場の課題、製品パイプライン分析、市場動向、競争状況などの情報をお届けいたします。...About the Chronic Lymphocytic Leukemia (CLL) Therapeutics Market Cancer that starts from the hematopoietic stem cells of the bone-marrow is referred to as leukemia. Leukemia can be chronic or acute depending on the maturity of the cells. In addition, based on the bone marrow cells from which the cancer starts, leukemia can be categorized as lymphocytic or myeloid. Hence, leukemia can be broadly classified into four types: • Acute myeloid (or myelogenous) leukemia (AML) • Chronic myeloid (or myelogenous) leukemia (CML) • Acute lymphocytic (or lymphoblastic) leukemia (ALL) • CLL Technavio’s analysts forecast the global CLL therapeutics market to grow...
  • 骨髄異形成症候群（MDS）治療薬の世界市場2015-2019
    IRTNTR7587 / Technavio / 2016年1月20日 / 当調査レポートでは、骨髄異形成症候群（MDS）治療薬の世界市場について調査・分析し、エグゼクティブサマリー、市場概観、市場概観、業界の構造分析、疾患概要、骨髄異形成症候群（MDS）治療薬の世界市場規模及び予測、投与経路（ROA）別分析、市場シェア、地域別分析/市場規模、市場の成長要因、市場の課題、市場動向、競争状況、主要企業（ベンダー）分析などの情報をお届けいたします。...About Myelodysplastic Syndrome Myelodysplastic syndrome is a group of hematologic disorders that arise in the bone marrow and spread into the blood. The syndrome is characterized by the inability of the hematopoietic cells produced in the bone marrow to attain maturity. Cytological dysplasia is a common feature of the syndrome, progressing to acute myeloid leukemia in about 30% of individuals with myelodysplastic syndrome. The disease is age-related, mostly affecting people aged 60 and above. Smoking, exposure to radiation, contact with chemicals such as benzene, genetic mutations, and chemotherapy can cause myelodysplastic syndrome. Technavio’s analysts forecast the global myelodysplastic syndrome market...
  • 虚血性心疾患（IHD）治療薬の世界市場2015-2019
    IRTNTR6611 / Technavio / 2015年7月29日 / 当調査レポートでは、虚血性心疾患（IHD）治療薬の世界市場について調査・分析し、エグゼクティブサマリー、市場概観、業界の構造分析、虚血性心疾患（IHD）治療薬の世界市場規模及び予測、疾患別分析、製品パイプライン分析、市場シェア、地域別分析、購買基準、市場成長要因、市場の課題、市場動向、競争状況、主要企業（ベンダー）分析などの情報をお届けいたします。...About IHD IHD is an abnormal condition of the human body marked by narrowing or blocking of the arteries that supply blood to the heart. It results from the buildup of plaque in the arteries. The condition often arises during excitement and exertion when heart requires more blood supply. This leads to recurrent chest pain and discomfort due to lack of sufficient blood supply, a condition known as angina pectoris. Prolonged blockage of the arteries due to lack of blood supply may result in death of tissues in the heart, leading to myocardial infarction. The symptoms develop slowly, and in...
  • むずむず脚症候群（RLS）治療薬の世界市場2015-2019
    IRTNTR6054 / Technavio / 2015年6月10日 / 当調査レポートでは、むずむず脚症候群（RLS）治療薬の世界市場について調査・分析し、エグゼクティブサマリー、市場概観、業界の構造分析、むずむず脚症候群（RLS）治療薬の世界市場規模及び予測、市場シェア、製品パイプライン分析、地域別分析、購買基準、市場成長要因、市場の課題、市場動向、競争状況、主要企業（ベンダー）分析などの情報をお届けいたします。...About RLS RLS is a neurological disease; it is also known as Willis-Ekbom disease. People with RLS experience an overwhelming desire to move their legs. It leads to an unpleasant pain in the limbs, leading to a disturbance in sleep pattern of patients. The condition aggravates at night or when the person is at rest. It occurs in both genders, but higher prevalence is seen in women than men. It affects people of all ages but mostly affecting the middle-aged and elderly people. Its common symptoms are uncomfortable itching pain in the legs, leading to a disruption in the sleep...
  • 慢性腎臓病（CKD）治療薬の世界市場2015-2019
    IRTNTR5417 / Technavio / 2015年3月11日 / 当調査レポートでは、慢性腎臓病（CKD）治療薬の世界市場について調査・分析し、エグゼクティブサマリー、市場概観、業界の構造分析、慢性腎臓病（CKD）治療薬の世界市場規模及び予測、市場シェア、地域別分析、購買基準、市場成長要因、市場の課題、市場動向、競争状況、主要企業（ベンダー）分析などの情報をお届けいたします。...According to WHO, CKD is not only common, treatable, and harmful but also a major contributing factor to the incidence and outcomes of at least three of the diseases that are targeted by WHO (hypertension, diabetes, and CVD). CKD is mainly defined as a reduced GFR, increased urinary albumin excretion, or both, and is growing public health issue. CKD is classified into five stages (stages 1-5) according to renal function and the level of urinary protein excretion as measured by eGFR which is derived from race, gender, age, and serum creatinine concentration. TechNavio's analysts forecast the Global CKD Drugs market...
  • クローン病（CD）治療薬の世界市場2015-2019
    IRTNTR5419 / Technavio / 2015年3月11日 / 当調査レポートでは、クローン病（CD）治療薬の世界市場について調査・分析し、エグゼクティブサマリー、市場概観、業界の構造分析、クローン病（CD）治療薬の世界市場規模及び予測、市場シェア、地域別分析、購買基準、市場成長要因、市場の課題、市場動向、競争状況、主要企業（ベンダー）分析などの情報をお届けいたします。...About CD CD is an ongoing condition that causes inflammation of the digestive tract or the GI tract. CD may also be named as ileitis, granulomatous enteritis or colitis, regional enteritis, or terminal ileitis. The exact etiology of CD is unknown. Usually, CD affects the small intestine and the beginning of the large intestine. However, the disease can disturb any part of the GI tract, from the mouth to the anus. CD can occur at any age; however, it is usually first diagnosed in people in their teens and twenties. TechNavio's analysts forecast the Global CD market to grow at...
  • 不安障害（Anxiety Disorder）治療薬の世界市場2015-2019
    IRTNTR5051 / Technavio / 2015年1月14日 / 当調査レポートでは、不安障害（Anxiety Disorder）治療薬の世界市場について調査・分析し、エグゼクティブサマリー、市場概観、業界の構造分析、不安障害（Anxiety Disorder）治療薬の世界市場規模及び予測、市場シェア、地域別分析、購買基準、市場成長要因、市場の課題、市場動向、競争状況、主要企業（ベンダー）分析などの情報をお届けいたします。...About Anxiety Disorders Anxiety is associated with uneasiness, fearfulness, and tension. Mild anxiety, for example, associated with exams or interview, is normal and triggers 'fight or flight' response. Anxiety without an identifiable cause, anxiety which persists even after the stressful condition is over, and anxiety which is out of proportion of the stressful condition indicates abnormal anxiety. However, severe and persistent anxiety can interfere with everyday activities and might lead to other psychic problems. Anxiety disorder is a mental health disorder characterized by the presence of anxiety. These disorders might occur simultaneously with other disorders such as depression, or along...
  • 強直性脊椎炎（Ankylosing Spondylitis）治療薬の世界市場2015-2019
    IRTNTR5050 / Technavio / 2015年1月7日 / 当調査レポートでは、強直性脊椎炎（Ankylosing Spondylitis）治療薬の世界市場について調査・分析し、エグゼクティブサマリー、市場概観、業界の構造分析、強直性脊椎炎（Ankylosing Spondylitis）治療薬の世界市場規模及び予測、種類別分析、作用機序別分析、投与経路（ROA）別分析、市場シェア、地域別分析、購買基準、市場成長要因、市場の課題、市場動向、競争状況、主要企業（ベンダー）分析などの情報をお届けいたします。...About Ankylosing Spondylitis Ankylosing spondylitis is a subtype of spondylarthropathy. The primary symptoms of the disease are inflammatory spinal pain with subsequent limitation of spine mobility and chest expansion. Ankylosing spondylitis can be diagnosed using clinical signs, radiological signs (sacroiliitis) and the presence of HLA-B27 antigen. According to the NIH and NIAMS, ankylosing spondylitis is a type of arthritis, which affects the joints in the vertebral column severely. It is a progressive inflammatory disease that typically becomes evident during early to mid-adulthood, as per NORD. It can also lead to the loss of spinal mobility for the affected individuals. The...
  • 急性骨髄性白血病（AML）治療薬の世界市場2015-2019
    IRTNTR4899 / Technavio / 2014年12月24日 / 当調査レポートでは、急性骨髄性白血病（AML）治療薬の世界市場について調査・分析し、エグゼクティブサマリー、市場概観、業界の構造分析、急性骨髄性白血病（AML）治療薬の世界市場規模及び予測、市場シェア、地域別分析、購買基準、市場成長要因、市場の課題、市場動向、競争状況、主要企業（ベンダー）分析などの情報をお届けいたします。...About Acute Myeloid Leukemia Acute myeloid leukemia, also known as acute myelogenous leukemia, is a hematopoietic disorder that starts either in hematopoietic stem cells or lineage-specific progenitor cells. Neoplasms arise from bone marrow, however, it spreads quickly into the blood. In the later stages of the disorder, it spreads to spleen, lymph node, liver, brain, spinal cord and testicles. Clonal expansion of the myeloid blasts and the loss of normal hematopoiesis are the main characteristic of acute myeloid leukemia. The disease affects the elderly people with age of 67 years. Fever, pallor, fatigue and hemorrhages are some of the clinical...

    • ◆H&Iグローバルリサーチ株式会社のお客様（例）◆